Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Elliquis

- PMLiVE

AbbVie, Biogen and Pfizer collaboration creates new resource for genetic exome sequence analysis

Companies have created 'world’s largest' resource for genetic exome sequence analysis

- PMLiVE

Israel study suggests Pfizer/BioNTech vaccine is less effective against Delta variant

Data suggests vaccine is 64% effective at preventing infection caused by Delta variant after two doses

- PMLiVE

BMS’s oral AML therapy Onureg receives EU approval

Onureg is the oral version of Vidaza, two of the drugs BMS gained as part of its acquisition of Celgene in 2019

- PMLiVE

BMS and Eisai to collaborate in deal worth up to $3.1bn

The two companies will work on developing a drug for endometrial, ovarian, lung and breast cancers

- PMLiVE

Pfizer/BioNTech, AZ vaccines effective against Delta COVID-19 variant after two doses

Pfizer/BioNTech and AZ vaccines found to be 96% and 92% effective against variant, respectively

- PMLiVE

US to donate 500 million Pfizer/BioNTech COVID-19 vaccine doses through COVAX

As part of the agreement, 500 million doses will be delivered between August 2021 and June 2022

- PMLiVE

Israel finds a ‘probable link’ between Pfizer vaccine and myocarditis cases

Reported cases increased following the second dose of the mRNA-based COVID-19 vaccine

- PMLiVE

BMS’ Zeposia gains FDA approval in ulcerative colitis

Treatment was initially approved in 2020 for multiple sclerosis

- PMLiVE

EMA authorises Pfizer/BioNTech’s COVID-19 vaccine for children aged 12 to 15

Clinical trial data recently showed that the vaccine is safe and effective in individuals in this age group

- PMLiVE

AZ, Pfizer/BioNTech COVID-19 vaccines ‘highly effective’ against Indian variant

UK study finds vaccines are likely to be effective in preventing hospitalisation/death

- PMLiVE

Pfizer to evaluate its pneumococcal vaccine alongside COVID-19 booster jab

Trial will enrol 600 adults, aged 65 and older, from the phase 3 Pfizer/BioNTech COVID-19 vaccine trial

- PMLiVE

BMS links up with Exscientia for $1.2bn AI drug discovery deal

Deal focuses on the use of AI to discover drug candidates across a number of therapeutic areas

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links